ERCC1、XRCC1单核苷酸多态性与鼻咽癌放化疗敏感性的相关性研究  

Relationship Between Single Nucleotide Polymorphisms of ERCC1,XRCC1 and Efficacy of Radiochemotherapy in Patients with Nasopharyngeal Cancer

作　　者：张和平[1] 张栋[1] 徐恩赐[1] 刘永萍[1] 周健[1] ZHANG He-ping ZHANG Dong XU En-ci et al(Changzhou Cancer Hospital of Soochow University, Changzhou 213001, China)

机构地区：[1]苏州大学附属常州肿瘤医院,江苏常州213001

出　　处：《肿瘤学杂志》2017年第1期40-44,共5页Journal of Chinese Oncology

基　　金：常州市卫生局重大项目(ZD201114)

摘　　要：[目的]初步探讨ERCC1、XRCC1单核苷酸多态性与鼻咽癌患者放疗敏感性的关系。[方法]经病理确诊且未经放疗、化疗或手术治疗的无远处转移鼻咽癌患者100例,接受顺铂单药同步放化疗,采用Taq Man探针实时荧光定量聚合酶链反应(polymerase chain reaction,PCR)法和直接测序法对患者外周血ERCC1、XRCC1进行多态性分析,患者同步放化疗结束后及治疗后3个月复查鼻咽部磁共振成像(MRI)测量肿瘤大小,进而分析ERCC1、XRCC1基因型与鼻咽癌同步放化疗近期治疗敏感性及远期生存率的关系。[结果 ]ERCC1、XRCC1基因多态性与鼻咽癌放化疗的短期疗效无关(均P>0.05),携带ERCC1C/C、C/T+T/T基因型患者放化疗后1年、2年、3年生存率分别为97.7%、94.3%、86.3%和98.2%、87.4%、73.8%,两组间比较差异有统计学意义(P<0.05);携带XRCC1G/G、A/A+G/A基因型患者放化疗后1年、2年、3年生存率分别为97.7%、91%、86.4%和86.9%、82.3%、69.6%,两组间比较差异有统计学意义(P<0.05)。[结论]ERCC1、XRCC1基因多态性与鼻咽癌同步放化疗的短期疗效无相关性,但与生存期有相关性,因此可以作为鼻咽癌放化疗生存期的预测指标。[Objective] To investigate the relationship between single nucleotide polymorphisms（SNP） of ERCC1,XRCC1 genes and efficacy of radiochemotherapy in patients with nasopharyngeal cancer（NPC）. [Methods] One hundred patients with pathologically proved NPC received first-line cispatin-based concurrent radiochemotherapy. SNPs in ERCC1 and XRCC1 were assessed with 5＇ nuclease allelic discrimination assay（Taq Man） by real-time polymerase chain reaction（RT-PCR） and direct sequencing. The size of tumor was measured by magnetic resonance imaging（MRI） after treatment completion and 3 years after treatment.The relationship between genotypes of ERCC1,XRCC1 and short-term response and overall survival was analyzed. [Results] The short-term response of chemo-radiotherapy showed no significant correlation with the polymorphisms of ERCC1（118） and XRCC1（399） genes（P〈0.05）. The 1-,2-,3-year overall survival rates after radiochemotherapy in patients with genotypes of C/C and C/T ＋T/T of ERCC1 were97.7%,94.3%,86.3%,and 98.2%,87.4%,73.8%,respectively（P〉0.05）. The 1-,2-,3-year overall survival rates after radiochemotherapy in patients with genotypes of G/G and A/A＋G/A of XRCC1（399） were 97.7%,94.3%,86.3% and 98.2%,87.4%,73.8%,respectively（P〈0.05）. [Conclusion]Polymorphisms of ERCC1 and XRCC1 in NPC have no correlation with the short-term response of radiochemotherapy,but have significant correlation with overall survival of patients. Polymorphisms of ERCC1 and XRCC1 may be used as predictors of survival for NPC patients receiving radiochemotherapy.

关 键 词：基因多态性 同步放化疗 敏感性 ERCC1 XRCC1 鼻咽肿瘤 

分 类 号：R739.63[医药卫生—肿瘤]